Total Payments
$1.4M
2024 Payments
$134,678
Companies
75
Transactions
1,834
Medicare Patients
17,330
Medicare Billing
$3.5M
Payment Breakdown by Category
Other$1.2M (91.1%)
Food & Beverage$44,255 (3.3%)
Travel$41,608 (3.1%)
Consulting$34,775 (2.6%)
Education$472.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 485 | 89.4% |
| Food and Beverage | $44,255 | 1,231 | 3.3% |
| Travel and Lodging | $41,608 | 81 | 3.1% |
| Consulting Fee | $34,775 | 13 | 2.6% |
| Long term medical supply or device loan | $11,458 | 2 | 0.8% |
| Honoraria | $7,200 | 3 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,000 | 3 | 0.3% |
| Education | $472.00 | 16 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $323,150 | 283 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $312,644 | 275 | $0 (2024) |
| Novo Nordisk Inc | $172,228 | 98 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $161,566 | 208 | $0 (2024) |
| Lilly USA, LLC | $136,079 | 126 | $0 (2024) |
| Medtronic, Inc. | $59,535 | 72 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $38,417 | 31 | $0 (2024) |
| Relypsa, Inc. | $33,845 | 45 | $0 (2019) |
| Medtronic Vascular, Inc. | $29,059 | 51 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $14,482 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $134,678 | 209 | Bayer Healthcare Pharmaceuticals Inc. ($36,699) |
| 2023 | $112,672 | 226 | Novo Nordisk Inc ($37,497) |
| 2022 | $185,512 | 262 | Novo Nordisk Inc ($84,499) |
| 2021 | $126,746 | 184 | Boehringer Ingelheim Pharmaceuticals, Inc. ($38,713) |
| 2020 | $85,208 | 152 | Lilly USA, LLC ($32,081) |
| 2019 | $212,959 | 256 | Janssen Pharmaceuticals, Inc ($86,554) |
| 2018 | $250,026 | 281 | Boehringer Ingelheim Pharmaceuticals, Inc. ($78,858) |
| 2017 | $249,791 | 264 | Novartis Pharmaceuticals Corporation ($94,800) |
All Payment Transactions
1,834 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | AngioDynamics, Inc. | Auryon Laser System 100-120 Vac (Device) | Long term medical supply or device loan | In-kind items and services | $7,500.00 | General |
| Category: ET | ||||||
| 12/30/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/20/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Obesity | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.32 | General |
| 12/17/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/17/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/12/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $10.60 | General |
| Category: Cardiology | ||||||
| 12/11/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $102.46 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/11/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/10/2024 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: EndoVenous Therapies | ||||||
| 12/09/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $99.09 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/02/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/02/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/27/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $95.76 | General |
| Category: Cardiology | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.23 | General |
| 11/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,450.00 | General |
| Category: DIABETES | ||||||
| 11/25/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/14/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,938.00 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,100.00 | General |
| Category: Diabetes | ||||||
| 11/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Cardio-renal | ||||||
| 11/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 51 | 4,859 | 12,561 | $3.1M | $868,061 |
| 2022 | 55 | 4,219 | 10,085 | $3.2M | $914,702 |
| 2021 | 51 | 3,740 | 10,167 | $2.9M | $872,788 |
| 2020 | 50 | 4,512 | 10,541 | $2.8M | $853,886 |
Total Patients
17,330
Total Services
43,354
Medicare Billing
$3.5M
Procedure Codes
209
All Medicare Procedures & Services
209 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 37225 | Removal of plaque in arteries of leg | Office | 2023 | 17 | 19 | $515,631 | $133,028 | 25.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 283 | 287 | $316,221 | $96,224 | 30.4% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 116 | 116 | $245,108 | $76,262 | 31.1% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 283 | 574 | $114,800 | $58,773 | 51.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 326 | 741 | $167,531 | $48,602 | 29.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 269 | 1,083 | $279,750 | $46,361 | 16.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 287 | 317 | $156,821 | $42,645 | 27.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 207 | 732 | $117,120 | $36,349 | 31.0% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 194 | 195 | $116,220 | $34,211 | 29.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 180 | 236 | $108,560 | $33,790 | 31.1% |
| 36482 | Chemical destruction of first incompetent vein of arm or leg using imaging guidance | Office | 2023 | 19 | 22 | $93,552 | $28,847 | 30.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 199 | 202 | $96,354 | $26,467 | 27.5% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 167 | 179 | $85,535 | $23,764 | 27.8% |
| 36475 | Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | Office | 2023 | 19 | 25 | $69,628 | $21,729 | 31.2% |
| 37252 | Ultrasound evaluation of blood vessel with review by radiologist, initial vessel | Office | 2023 | 24 | 28 | $82,520 | $21,388 | 25.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 142 | 406 | $50,344 | $15,742 | 31.3% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 195 | 316 | $39,182 | $11,693 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 71 | 89 | $28,173 | $9,155 | 32.5% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 85 | 288 | $29,088 | $8,957 | 30.8% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 100 | 103 | $33,472 | $8,366 | 25.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 163 | 166 | $23,612 | $7,408 | 31.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 85 | 85 | $24,422 | $7,125 | 29.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 73 | 160 | $20,000 | $6,272 | 31.4% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 163 | 166 | $18,300 | $5,657 | 30.9% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 40 | 43 | $19,436 | $5,116 | 26.3% |
About Tamam Mohamad
Tamam Mohamad is a Cardiovascular Disease healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2009. The National Provider Identifier (NPI) number assigned to this provider is 1457687584.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Tamam Mohamad has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $134,678 received in 2024. These payments were reported across 1,834 transactions from 75 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
As a Medicare-enrolled provider, Mohamad has provided services to 17,330 Medicare beneficiaries, totaling 43,354 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 209 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties General Acute Care Hospital, Interventional Cardiology
- Location Detroit, MI
- Active Since 10/24/2009
- Last Updated 04/23/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1457687584
Products in Payments
- JARDIANCE (Drug) $439,728
- XARELTO (Drug) $312,644
- ENTRESTO (Drug) $160,934
- Ozempic (Drug) $113,513
- VENASEAL (Device) $39,830
- Kerendia (Drug) $38,417
- Veltassa (Drug) $33,845
- ClosureFast (Device) $28,611
- VenaSeal (Device) $19,541
- Rybelsus (Drug) $14,525
- BRILINTA (Drug) $14,225
- TRULICITY (Drug) $13,833
- Auryon Laser System 100-120 Vac (Device) $11,458
- LifeVest (Device) $10,308
- Impella (Device) $7,766
- RYBELSUS (Drug) $7,013
- PRALUENT (Drug) $5,048
- FLEXITOUCH PLUS (Device) $4,746
- PRALUENT ALIROCUMAB INJECTION (Biological) $4,636
- Peripheral Orbital Atherectomy System (Device) $4,459
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Detroit
Wayne Douglas Weaver, M.d, M.D
Cardiovascular Disease — Payments: $360,582
Cardiovascular Disease $360,582
Dr. Brian O'neill, M.d, M.D
Cardiovascular Disease — Payments: $182,193
Cardiovascular Disease $182,193
Dr. Brian Ference, Md, MD
Cardiovascular Disease — Payments: $160,503
Cardiovascular Disease $160,503
David Lanfear, M.d, M.D
Cardiovascular Disease — Payments: $160,449
Cardiovascular Disease $160,449
Dr. Mahir Elder, Md, MD
Cardiovascular Disease — Payments: $132,144
Cardiovascular Disease $132,144
Dr. Zaher Hakim, M.d, M.D
Cardiovascular Disease — Payments: $93,632
Cardiovascular Disease $93,632